Accelerating Therapies

We aim to fast-track science, fund innovative research, and push progress forward to uncover the next generation therapies. With this integrated approach, our goal is to stop PF in its tracks.

RESEARCH

What We Do

Three Lakes Consortium for PF (TLC4PF)

The Three Lakes Consortium for PF (TLC4PF) aims to accelerate therapies for the treatment of PF.

B4PF: Understanding Early Disease

To develop therapies that prevent the development of PF, it is essential to study the earliest aspects of disease pathogenesis.

A Global Collaboration for PF

Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is a clinically focused research program funded by the Australian National Health and Medical Research Council.

The PRECISIONS Study

Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) is a comprehensive, multicenter, and multi-investigator study.

Enlil Therapeutics

Three Lakes Foundation has provided funding to support Enlil Therapeutics in its quest to identify compounds that activate telomerase.

Breath Biopsy for Early PF Detection

Metabolic changes associated with IPF and interstitial lung abnormality (ILA) may lead to the production of unique, volatile, organic compounds (VOCs) detectable in breath.